Dr. Randell Correia Suggests How to Control Costs in Specialty Pharmacy

Randell "RJ" Correia, PharmD, Senior Vice President, Pharmacy Services, Optum Rx, addresses the rapid rise of specialty pharmacy spending. Dr. Correia discusses the possible complications health reform exchanges may cause and the impact they will have on the future of pharmacy benefit drug management.

Related Videos

Related Content

Advertisement

October 3rd 2024

What the Approval of Isatuximab Plus VRd Adds to Multiple Myeloma Care

Hayden E. Klein Maggie L. Shaw

Surbhi Sidana, MD, MBBS, shares how the addition of an anti-CD38 antibody to the VRd regimen significantly improves progression-free survival for patients with transplant-ineligible multiple myeloma.

September 30th 2024

Sustaining Compassionate Trauma Care Across Communities

Maggie L. Shaw

September is National Recovery Month, and we are bringing you another limited-edition month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In our final episode, we speak with Lyndra Bills, MD, and Shari Hutchison, MS.

October 2nd 2024

Isatuximab Approval Highlights Role of Anti-CD38 Antibody in Myeloma Care

Maggie L. Shaw

On September 20, the FDA approved isatuximab plus bortezomib, lenalidomide, and dexamethasone in the first line for patients who have multiple myeloma and are ineligible for transplant.

September 27th 2024

Frameworks for Advancing Health Equity: Community Wellness Centers

Giuliana Grossi

Delia Orosco, MS, director of Community Wellness Centers at Inland Empire Health Plan, shares insight into innovative initiatives provided by the wellness centers and their new mobile mammogram clinics.

October 1st 2024

Achieving the Goals of Value-Based Care for Multiple Sclerosis

Skylar Jeremias

Value-based agreements come with risks and benefits, but a health system’s existing facilities and initiatives can help support the goals associated with them, JT Lew, PharmD, MBA, a managed care pharmacist at MultiCare Health System, explained.

September 30th 2024

Amivantamab Presents an Exciting Treatment Opportunity in NSCLC

Maggie L. Shaw

In less than a month, from August 20 to September 19, amivantamab (Ami; Rybrevant, Johnson & Johnson) received 2 approvals from the FDA for use in non–small cell lung cancer (NSCLC).

Related Content

Advertisement

October 3rd 2024

What the Approval of Isatuximab Plus VRd Adds to Multiple Myeloma Care

Hayden E. Klein Maggie L. Shaw

Surbhi Sidana, MD, MBBS, shares how the addition of an anti-CD38 antibody to the VRd regimen significantly improves progression-free survival for patients with transplant-ineligible multiple myeloma.

September 30th 2024

Sustaining Compassionate Trauma Care Across Communities

Maggie L. Shaw

September is National Recovery Month, and we are bringing you another limited-edition month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In our final episode, we speak with Lyndra Bills, MD, and Shari Hutchison, MS.

October 2nd 2024

Isatuximab Approval Highlights Role of Anti-CD38 Antibody in Myeloma Care

Maggie L. Shaw

On September 20, the FDA approved isatuximab plus bortezomib, lenalidomide, and dexamethasone in the first line for patients who have multiple myeloma and are ineligible for transplant.

September 27th 2024

Frameworks for Advancing Health Equity: Community Wellness Centers

Giuliana Grossi

Delia Orosco, MS, director of Community Wellness Centers at Inland Empire Health Plan, shares insight into innovative initiatives provided by the wellness centers and their new mobile mammogram clinics.

October 1st 2024

Achieving the Goals of Value-Based Care for Multiple Sclerosis

Skylar Jeremias

Value-based agreements come with risks and benefits, but a health system’s existing facilities and initiatives can help support the goals associated with them, JT Lew, PharmD, MBA, a managed care pharmacist at MultiCare Health System, explained.

September 30th 2024

Amivantamab Presents an Exciting Treatment Opportunity in NSCLC

Maggie L. Shaw

In less than a month, from August 20 to September 19, amivantamab (Ami; Rybrevant, Johnson & Johnson) received 2 approvals from the FDA for use in non–small cell lung cancer (NSCLC).